Israeli Study Reveals Pfizer Vaccine’s Real-World Efficiency Against COVID-19

Pfizer’s Coronavirus vaccine offers 94% protection against symptomatic COVID-19 infection in a real-world environment, a large-scale study involving 1.2 million people in Israel has revealed.

Published in the New England Journal of Medicine, the study confirms the power of mass vaccination campaigns to break the chain of transmission of the Coronavirus.

ALSO READ

Ramiz Raja’s YouTube Channel Gets Hacked

According to details, the study was conducted between 20 December 2020 and 1 February 2021, a period during which the UK’s Coronavirus strain was wreaking havoc in Israel.

Israeli researchers performed the study by dividing the 1.2 million people into two equal groups; vaccinated and unvaccinated.

They then compared each participant from the vaccinated group with another participant of the unvaccinated group having the same age, gender, geographic, medical and other characteristics.

The researchers then recorded the outcomes of the vaccinated group at days 14-20 after the first of the two doses and days 7 or more after the second dose.

ALSO READ

Pakistan and India Announce a Historic Decision on LoC

They found that the vaccine offered 57% protection against symptomatic Coronavirus infection between 14-20 days after the first dose which increased to 94% after 7 days of the second dose.

The study claims that people who received both doses had a 92% lower chance of getting any form of COVID-19 infection and undergoing hospitalization due to it when compared to those who were unvaccinated.